Momenta Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Momenta Pharmaceuticals Inc.

MNTA 52.48

0.0%

Oct 2 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Biomaven	12/28/2010 4:33:24 PM
	Read Replies (3) of 3027

Amphastar modified complaint: fdanewspubs.com A couple of quotes: In November 2006, a member of the staff of the FDA’s Office of Generic Drugs called Amphastar to say that Amphastar’s enoxaparin ANDA would be approved within ten to fourteen business days. Despite this verbal assurance, Amphastar’s enoxaparin ANDA remains in limbo. ... On November 2, 2007, the FDA acknowledged, in a letter to Amphastar from the Office of Generic Drugs, that Amphastar had met the FDA’s five “sameness” criteria and therefore had demonstrated its enoxaparin’s sameness with Lovenox® in its ANDA. The "sameness" finding was subsequently rescinded because of a change in raw materials supplier. Current hold-up seems to be supply and perhaps immunogenicity. If the FDA has truly acknowledged "sameness" according to the five criteria as Amphastar claims, then Teva's claim to have achieved sameness must also get a boost in credibility. (I currently have no position in MNTA). Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next